Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Transgene logo — Immunotherapy against cancer. 4 clinical-stage products. 2 n...

Transgene

Immunotherapy against cancer. 4 clinical-stage products. 2 novel platforms: Invir.IO™ and myvac®

Founded 1979 France France 213 employees Post-IPO Equity Total: $82.50M Biotechnology, Manufacturing +1

General Information

Company Name Transgene
Founded Year 1979
Location France France
Employees 213
Industries Biotechnology, Manufacturing, Pharmaceutical
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with Transgene. To contact Transgene, visit transgene.fr.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Transgene compare?

A PDF of Transgene and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Transgene soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Transgene

Transgene is a pioneering biotechnology company established in 1979, headquartered in France. The company focuses on advancing cancer treatment through its innovative immunotherapy solutions. With a slogan promoting "Immunotherapy against cancer," Transgene offers four clinical-stage products backed by its cutting-edge platforms: Invir.IO™ and myvac®.

The company operates within the Biotechnology, Manufacturing, and Pharmaceutical industries, leveraging decades of experience. These strengths position Transgene as a notable player in the biopharmaceutical sector, striving to improve patient outcomes in oncology.

Following its strategic trajectory, the firm recently attracted a €14.00M post-IPO equity investment on 17 July 2023. Although investor details were not disclosed, this capital infusion underscores confidence in Transgene's robust potential. As Transgene continues to advance its clinical pipeline, it presents an attractive opportunity for investors targeting innovation-driven growth in the healthcare sector.

Business keywords: immunotherapy, cancer treatment, clinical-stage products, Invir.IO™ platform, myvac® platform, biopharmaceutical, immunotherapeutic products, chronic infectious diseases, clinical trials, clinical batch manufacturing, oncology

Services & Products

Development of personalized therapeutic vaccines
Design and implementation of oncolytic virus therapies
Research and development in immunotherapy
Advanced engineering technology applications

Target Customers

Cancer patients Pharmaceutical companies Biotechnology researchers Healthcare providers

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity €14.00M -
17 Jul 2023
Post IPO Equity €34.10M -
22 Jun 2021
Post IPO Debt €20.00M 1
Natixis
02 Apr 2019
Post IPO Equity €14.40M -
10 Nov 2017

Transgene Alternatives & Competitors

View All Alternatives
Transgene vs
Checkmate Pharmaceuticals
Checkmate Pharmaceuticals

Pioneering advanced immunotherapies to amplify cancer treatment options and improve patient outcomes...

Series C
11-50 employees
Biotechnology, Health and Wellness
Transgene vs
Glycyx
Glycyx United States

Restoring immune response in cancer: reversing Opioid-Induced Immunodeficiency to enhance immunother...

Series A
3 employees
Biopharma, Biotechnology
Transgene vs
Barinthus Biotherapeutics
Barinthus Biotherapeutics United Kingdom

Barinthus is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutic ca...

Acquired
34 employees
Biotechnology, Health and Wellness
View all alternatives

FAQ About Transgene

Immunotherapy against cancer. 4 clinical-stage products. 2 novel platforms: Invir.IO™ and myvac®
Transgene was founded in 1979.
Transgene is headquartered in France.
Transgene operates in Biotechnology, Manufacturing and Pharmaceutical. Its work centres on immunotherapy, cancer treatment, clinical-stage products and Invir.IO™ platform. Its customers include Cancer patients, Pharmaceutical companies and Biotechnology researchers.
Transgene has approximately 213 employees.
Transgene has completed 4 funding rounds, raising a total of $82.50M. The latest funding stage is Post-IPO Equity.
Transgene offers: Development of personalized therapeutic vaccines, Design and implementation of oncolytic virus therapies, Research and development in immunotherapy, Advanced engineering technology applications.
Top alternatives and competitors to Transgene include Checkmate Pharmaceuticals, Glycyx, Barinthus Biotherapeutics, Imvax, Inc., Cybrexa Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Transgene and Checkmate Pharmaceuticals are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Transgene, https://bouncewatch.com/company/transgene, updated 17 September 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes